MedWatch

FDA approves Ascendis' weekly growth hormone

A growth hormone for weekly use made by Denmark's Ascendis Pharma may now be commercialized in the US after the public authority approved the company's treatment, Skytrofa.

Photo: Kevin Grønnemann

Danish biotechnology company Ascendis Pharma is now permitted to send its first medication to market in the US.

Wednesday evening, the listed company informs that the US Food & Drug Administration has rubber stamped Trancon hGH, a weekly growth growth hormone to be henceforth marketed by under trademark Skytrofa.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs